1. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study
- Author
-
Gregory L. Calligaro, Usha Lalla, Gordon Audley, Phindile Gina, Malcolm G. Miller, Marc Mendelson, Sipho Dlamini, Sean Wasserman, Graeme Meintjes, Jonathan Peter, Dion Levin, Joel A. Dave, Ntobeko Ntusi, Stuart Meier, Francesca Little, Desiree L. Moodley, Elizabeth H. Louw, Andre Nortje, Arifa Parker, Jantjie J. Taljaard, Brian W. Allwood, Keertan Dheda, and Coenraad F.N. Koegelenberg
- Subjects
COVID-19 ,Ventilation ,High flow nasal oxygen ,Pneumonia ,Medicine (General) ,R5-920 - Abstract
Background: The utility of heated and humidified high-flow nasal oxygen (HFNO) for severe COVID-19-related hypoxaemic respiratory failure (HRF), particularly in settings with limited access to intensive care unit (ICU) resources, remains unclear, and predictors of outcome have been poorly studied. Methods: We included consecutive patients with COVID-19-related HRF treated with HFNO at two tertiary hospitals in Cape Town, South Africa. The primary outcome was the proportion of patients who were successfully weaned from HFNO, whilst failure comprised intubation or death on HFNO. Findings: The median (IQR) arterial oxygen partial pressure to fraction inspired oxygen ratio (PaO2/FiO2) was 68 (54–92) in 293 enroled patients. Of these, 137/293 (47%) of patients [PaO2/FiO2 76 (63–93)] were successfully weaned from HFNO. The median duration of HFNO was 6 (3–9) in those successfully treated versus 2 (1–5) days in those who failed (p
- Published
- 2020
- Full Text
- View/download PDF